Skip to main content
. 2015 Oct 2;309(12):L1447–L1454. doi: 10.1152/ajplung.00262.2015

Fig. 3.

Fig. 3.

Axitinib attenuates VEGF-D upregulation in serum and lung lining fluid. Serum and bronchoalveolar lavage (BAL) fluid was collected from control mice or mice with Tsc2-null lesions treated with diluent or axitinib and analyzed for VEGF-D level. A: serum samples were analyzed for VEGF-D level by ELISA kit. Values are means ± SE from triplicate measurements and shown as picograms of VEGF-D per milliliter of sample; n = 10 per each group. P < 0.05 vs. *control/diluent group and #Tsc2-null/diluent group by two-way ANOVA and Bonferroni correction for multiple comparisons. B, top: representative micrographs of BAL VEGF-D protein content. BAL samples containing equal volume were subjected to SDS-PAGE under reduced conditions followed by immunoblotting with anti-VEGF-D antibody. Bottom: densitometric quantification of VEGF-D content. Mean values of all of the samples from Tsc2-null lung treated with diluent or axitinib were calculated and presented as a percentage of Tsc2-null lungs treated with diluent. Values are means ± SE; n = 10 per group. P < 0.05 vs. *control/diluent group and #Tsc2-null/diluent group by t-test.